[go: up one dir, main page]

WO2021203030A3 - Methods of use of anti-trem2 antibodies - Google Patents

Methods of use of anti-trem2 antibodies Download PDF

Info

Publication number
WO2021203030A3
WO2021203030A3 PCT/US2021/025626 US2021025626W WO2021203030A3 WO 2021203030 A3 WO2021203030 A3 WO 2021203030A3 US 2021025626 W US2021025626 W US 2021025626W WO 2021203030 A3 WO2021203030 A3 WO 2021203030A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
trem2 antibodies
trem2
antibodies
matured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/025626
Other languages
French (fr)
Other versions
WO2021203030A2 (en
Inventor
Robert Paul
Michael F. Ward
Hua Long
Omer Rizwan SIDDIQUI
Arnon Rosenthal
Felix Leejia YEH
Sam Jackson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alector LLC
Original Assignee
Alector LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector LLC filed Critical Alector LLC
Priority to IL296992A priority Critical patent/IL296992A/en
Priority to EP21721714.0A priority patent/EP4126953A2/en
Priority to KR1020227038069A priority patent/KR20230005848A/en
Priority to JP2022560204A priority patent/JP2023520516A/en
Priority to AU2021247286A priority patent/AU2021247286A1/en
Priority to US17/916,728 priority patent/US20230183341A1/en
Priority to BR112022019892A priority patent/BR112022019892A2/en
Priority to CN202180037525.0A priority patent/CN115667308A/en
Priority to CA3172451A priority patent/CA3172451A1/en
Priority to MX2022012182A priority patent/MX2022012182A/en
Publication of WO2021203030A2 publication Critical patent/WO2021203030A2/en
Publication of WO2021203030A3 publication Critical patent/WO2021203030A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nuclear Medicine (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a TREM2 protein, e.g., human TREM2, for use in treating and/or delaying progression of a disease or injury in an individual in need thereof.
PCT/US2021/025626 2020-04-03 2021-04-02 Methods of use of anti-trem2 antibodies Ceased WO2021203030A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IL296992A IL296992A (en) 2020-04-03 2021-04-02 Methods for using anti-trem2 antibodies
EP21721714.0A EP4126953A2 (en) 2020-04-03 2021-04-02 Methods of use of anti-trem2 antibodies
KR1020227038069A KR20230005848A (en) 2020-04-03 2021-04-02 Methods of Using Anti-TREM2 Antibodies
JP2022560204A JP2023520516A (en) 2020-04-03 2021-04-02 Method of using anti-TREM2 antibody
AU2021247286A AU2021247286A1 (en) 2020-04-03 2021-04-02 Methods of use of anti-TREM2 antibodies
US17/916,728 US20230183341A1 (en) 2020-04-03 2021-04-02 Methods of use of anti-trem2 antibodies
BR112022019892A BR112022019892A2 (en) 2020-04-03 2021-04-02 METHODS FOR TREATMENT AND/OR DELAYING THE PROGRESSION OF A DISEASE OR INJURY AND FOR MONITORING THE TREATMENT OF AN INDIVIDUAL
CN202180037525.0A CN115667308A (en) 2020-04-03 2021-04-02 Methods of use of anti-TREM 2 antibodies
CA3172451A CA3172451A1 (en) 2020-04-03 2021-04-02 Methods of use of anti-trem2 antibodies
MX2022012182A MX2022012182A (en) 2020-04-03 2021-04-02 Methods of use of anti-trem2 antibodies.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063005130P 2020-04-03 2020-04-03
US63/005,130 2020-04-03
US202063079810P 2020-09-17 2020-09-17
US63/079,810 2020-09-17

Publications (2)

Publication Number Publication Date
WO2021203030A2 WO2021203030A2 (en) 2021-10-07
WO2021203030A3 true WO2021203030A3 (en) 2021-11-18

Family

ID=75674977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/025626 Ceased WO2021203030A2 (en) 2020-04-03 2021-04-02 Methods of use of anti-trem2 antibodies

Country Status (11)

Country Link
US (1) US20230183341A1 (en)
EP (1) EP4126953A2 (en)
JP (1) JP2023520516A (en)
KR (1) KR20230005848A (en)
CN (1) CN115667308A (en)
AU (1) AU2021247286A1 (en)
BR (1) BR112022019892A2 (en)
CA (1) CA3172451A1 (en)
IL (1) IL296992A (en)
MX (1) MX2022012182A (en)
WO (1) WO2021203030A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3601358T (en) * 2017-08-03 2023-08-10 Alector Llc ANTI-TREM2 ANTIBODIES AND METHODS OF USING THEM
MX2023014113A (en) * 2021-05-28 2024-02-13 Vigil Neuroscience Inc Trem2 agonist biomarkers and methods of use thereof.
CA3225302A1 (en) * 2021-07-09 2023-01-12 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
IL314896A (en) * 2022-02-23 2024-10-01 Alector Llc Methods for using anti-TREM2 antibodies
WO2023192282A1 (en) * 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
CN117624360A (en) 2022-08-26 2024-03-01 南京融捷康生物科技有限公司 A kind of single domain antibody against TREM2 and its use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062672A2 (en) * 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof
WO2018195506A1 (en) * 2017-04-21 2018-10-25 Amgen Inc. Trem2 antigen binding proteins and uses thereof
WO2019028292A1 (en) * 2017-08-03 2019-02-07 Alector Llc Anti-trem2 antibodies and methods of use thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (en) 1991-10-07 1994-05-27 Oncologix Inc Combination and method of use of anti-erbB-2 monoclonal antibodies
ATE207080T1 (en) 1991-11-25 2001-11-15 Enzon Inc MULTIVALENT ANTIGEN-BINDING PROTEINS
DE69334255D1 (en) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker for cancer and biosynthetic binding protein for it
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
KR100654645B1 (en) 1995-04-27 2007-04-04 아브게닉스, 인크. Human Antibodies from Immunized Genomous
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP2002514895A (en) 1995-09-28 2002-05-21 アレクション、ファーマスーティカルズ、インコーポレーテッド Pig cell interacting protein
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
CA2312208C (en) 1997-12-05 2011-01-25 The Scripps Research Institute Humanization of murine antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7105825B2 (en) * 1999-04-14 2006-09-12 Juni Jack E Single photon emission computed tomography system
WO2004042072A2 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
MX2007008017A (en) 2004-12-31 2007-09-12 Genentech Inc Polypeptides that bind br3 and uses thereof.
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
EP3167888B1 (en) 2006-03-15 2024-05-01 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
UY30776A1 (en) 2006-12-21 2008-07-03 Medarex Inc CD44 ANTIBODIES
CA3187687A1 (en) 2007-09-14 2009-03-19 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA3117920A1 (en) 2010-07-16 2012-01-19 Adimab, Llc Libraries comprising segmental pools, and methods for their preparation and use
JP6474010B2 (en) * 2014-09-26 2019-02-27 サン パテント トラスト COMMUNICATION DEVICE, COMMUNICATION METHOD, AND INTEGRATED CIRCUIT
WO2017201539A1 (en) * 2016-05-20 2017-11-23 Cedars-Sinai Medical Center Methods of treating or preventing alzheimer's disease and associated conditions
CA3030785A1 (en) 2016-07-22 2018-01-25 Deutsches Zentrum Fur Neurodegenerative Erkrankungen E.V. (Dzne) Trem2 cleavage modulators and uses thereof
EP3681909A1 (en) 2017-09-14 2020-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
JP2023505279A (en) * 2019-12-05 2023-02-08 アレクトル エルエルシー Method of using anti-TREM2 antibody
JP7745557B2 (en) * 2020-02-24 2025-09-29 アレクトル エルエルシー Methods of Use of Anti-TREM2 Antibodies
IL314896A (en) * 2022-02-23 2024-10-01 Alector Llc Methods for using anti-TREM2 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062672A2 (en) * 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof
WO2018195506A1 (en) * 2017-04-21 2018-10-25 Amgen Inc. Trem2 antigen binding proteins and uses thereof
WO2019028292A1 (en) * 2017-08-03 2019-02-07 Alector Llc Anti-trem2 antibodies and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CARECCHIO MIRYAM ET AL: "The role of osteopontin in neurodegenerative diseases", JOURNAL OF ALZHEIMER'S DISEASE, IOS PRESS, NL, vol. 25, no. 2, 1 January 2011 (2011-01-01), pages 179 - 185, XP009517375, ISSN: 1875-8908, DOI: 10.3233/JAD-2011-102151 *
HUAN LU ET AL: "Body fluid biomarkers in Alzheimer's disease", ANNALS OF TRANSLATIONAL MEDICINE, 1 April 2015 (2015-04-01), China, pages 70 - 70, XP055726478, Retrieved from the Internet <URL:https://atm.amegroups.com/article/view/6048/6780> DOI: 10.3978/j.issn.2305-5839.2015.02.13 *
QINGWEN CHENG ET AL: "TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer's disease variant Trem2 R47H on murine myeloid cell function", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 293, no. 32, 29 March 2018 (2018-03-29), US, pages 12620 - 12633, XP055657475, ISSN: 0021-9258, DOI: 10.1074/jbc.RA118.001848 *
SCHWABE TINA ET AL: "DEVELOPMENT OF TREM2 AGONISTIC ANTIBODIES TO TREAT ALZHEIMER'S DISEASE", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'SASSOCIATION, ELSEVIER, NEW YORK, NY, US, vol. 15, no. 7, 1 July 2019 (2019-07-01), XP085869761, ISSN: 1552-5260, [retrieved on 20191018], DOI: 10.1016/J.JALZ.2019.06.4560 *

Also Published As

Publication number Publication date
IL296992A (en) 2022-12-01
JP2023520516A (en) 2023-05-17
CN115667308A (en) 2023-01-31
MX2022012182A (en) 2022-12-08
WO2021203030A2 (en) 2021-10-07
BR112022019892A2 (en) 2022-12-13
US20230183341A1 (en) 2023-06-15
EP4126953A2 (en) 2023-02-08
AU2021247286A1 (en) 2022-10-20
KR20230005848A (en) 2023-01-10
CA3172451A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
WO2021203030A3 (en) Methods of use of anti-trem2 antibodies
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
PH12019502463A1 (en) Anti-cd33 antibodies and methods of use thereof
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
EP3991748A3 (en) Anti-sortilin antibodies and methods of use thereof
MX2021000933A (en) Anti-siglec-5 antibodies and methods of use thereof.
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
PH12022550239A1 (en) Anti-ms4a4a antibodies and methods of use thereof
NZ759835A (en) Cd38 modulating antibody
PH12022551398A1 (en) Anti-mertk antibodies and methods of use thereof
MX2021015212A (en) ANTISORTILINE ANTIBODIES FOR USE IN THERAPY.
ZA202008095B (en) Humanized antibodies against psma
WO2020091635A3 (en) Monoclonal antibodies against the beta chain region of human trbv9
PH12021551535A1 (en) Monoclonal antibodies that bind specifically to human trbv9
ZA202302392B (en) Antibodies against ilt2 and use thereof
MX2022007156A (en) Methods of use of anti-cd33 antibodies.
WO2022261648A3 (en) Methods of use of anti-sortilin antibodies
CA3243760A1 (en) Methods of use of anti-trem2 antibodies
MX2023012300A (en) Human antibodies to artemin and methods of use thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21721714

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3172451

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022560204

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022019892

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2021247286

Country of ref document: AU

Date of ref document: 20210402

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2021721714

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2021721714

Country of ref document: EP

Effective date: 20221103

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 112022019892

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220930

WWW Wipo information: withdrawn in national office

Ref document number: 202292820

Country of ref document: EA